Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer.
Tsavaris N, Gennatas K, Kosmas C, Skopelitis HM, Gouveris P, Dimitrakopoulos A, Zacharakis M, Kouraklis G, Vasiliou J, Felekouras E, Voros D, Zografos G, Balafouta M, Paraskevaidis M, Safioleas M, Fotiadis K, Papastratis G, Karatzas G, Papalambros E. Tsavaris N, et al. Among authors: papastratis g. Oncol Rep. 2004 Oct;12(4):927-32. doi: 10.3892/or.12.4.927. Oncol Rep. 2004. PMID: 15375524 Clinical Trial.
Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
Tsavaris N, Kosmas C, Skopelitis H, Papadoniou N, Polyzos A, Zografos G, Adoniou E, Gryniatsos J, Felekouras E, Zacharakis M, Sigala F, Bacoyiannis C, Papastratis G, Papalambros E. Tsavaris N, et al. Among authors: papastratis g. Chemotherapy. 2007;53(4):282-91. doi: 10.1159/000102583. Epub 2007 May 10. Chemotherapy. 2007. PMID: 17496414 Clinical Trial.
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N, Ziras N, Kosmas C, Giannakakis T, Gouveris P, Vadiaka M, Dimitrakopoulos A, Karadima D, Rokana S, Papalambros E, Papastratis G, Margaris H, Tsipras H, Polyzos A. Tsavaris N, et al. Among authors: papastratis g. Cancer Chemother Pharmacol. 2003 Dec;52(6):514-9. doi: 10.1007/s00280-003-0659-z. Epub 2003 Sep 23. Cancer Chemother Pharmacol. 2003. PMID: 14504920 Clinical Trial.
Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.
Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H, Margaris H, Papastratis G, Tzima E, Papadoniou N, Karatzas G, Papalambros E. Tsavaris N, et al. Among authors: papastratis g. Invest New Drugs. 2004 Apr;22(2):193-8. doi: 10.1023/B:DRUG.0000011797.09549.53. Invest New Drugs. 2004. PMID: 14739669 Clinical Trial.
CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N, Kosmas C, Papadoniou N, Kopterides P, Tsigritis K, Dokou A, Sarantonis J, Skopelitis H, Tzivras M, Gennatas K, Polyzos A, Papastratis G, Karatzas G, Papalambros A. Tsavaris N, et al. Among authors: papastratis g. J Chemother. 2009 Dec;21(6):673-80. doi: 10.1179/joc.2009.21.6.673. J Chemother. 2009. PMID: 20071292
33 results